Skip to main content

Lluis Castells Fusté

Institutions of which they are part

Liver Diseases
Vall Hebron Institut de Recerca

Lluis Castells Fusté

Institutions of which they are part

Liver Diseases
Vall Hebron Institut de Recerca

Projects

Unitat de Recerca en Malalties Hepatobiliars

IP: Joan Genescà Ferrer
Collaborators: Immaculada Raurell Saborit, Antonio González Fernández, Lluis Castells Fusté, Francisco Rodríguez Frias, Silvia Sauleda Oliveras, Lluís Palenzuela Díaz, Victor Manuel Vargas Blasco, Maria Buti Ferret, Josep Quer Sivila, Maria Nieves Martell Pérez-Alcalde, Rafael Esteban Mur, Juan Ignacio Esteban Mur, David Tabernero Caellas
Funding agency: Agència Gestió Ajuts Universitaris i de Recerca
Funding: 54080
Reference: 2009 SGR 383
Duration: 01/01/2010 - 30/04/2014

Estudio doble ciego, aleatorizado y controlado sobre la eficacia de la administración combinada de albúmina y midodrina en la prevención de las complicaciones de pacientes con cirrosis en lista de espera de trasplante hepático

IP: Victor Manuel Vargas Blasco
Collaborators: Lluis Castells Fusté
Funding agency: Instituto de Salud Carlos III
Funding: 30250
Reference: EC07/90744
Duration: 01/11/2007 - 31/12/2011

Caracterización serológica, inmunologica y molecular de donantes de sangre con infección oculta por virus de la hepatitis B

IP: Silvia Sauleda Oliveras
Collaborators: Lluis Castells Fusté, Marta Bes Maijo, Maria Madeleine Piron
Funding agency: Instituto de Salud Carlos III
Funding: 45980
Reference: PI070754
Duration: 01/01/2008 - 30/12/2010

Selección y expansión de linfocitos CD4+NS3-específicos de pacientes VHC. caracterización del estado de anergia en cronicidad y restauración funcional para empleo en inmunoterapia adaptativa para prevención y tratamiento de la recurrencia postrasplante.

IP: Josep Quer Sivila
Collaborators: Itxarone Izaskun Bilbao Aguirre, Lluis Castells Fusté, Juan Ignacio Esteban Mur
Funding agency: Instituto de Salud Carlos III
Funding: 113740
Reference: PI061244
Duration: 01/01/2007 - 30/12/2009

Related news

Preliminary study results confirm that the drug resmetirom reduces the presence of fat, inflammation, cell damage and fibrosis in the liver.

The European project, in which Vall d'Hebron participates, will favor personalized diagnosis and innovative therapeutic strategies in patients with the disease.

The research team used nanotechnology to deliver the drug directly to liver cells, which eliminated side effects without reducing effectiveness.

Related professionals

Neus Gual Tarrada

Neus Gual Tarrada

Predoctoral researcher
Research on Aging, Frailty and Transitions in Barcelona
Read more
Ana Maria Nieto Montoya

Ana Maria Nieto Montoya

Administration and Management
Neuroradiology
Read more
Emma Granados Serra

Emma Granados Serra

Tècnic/a Grau Superior
Unitat legal
Direcció Jurídica
Read more
Óscar Mula Castellón

Óscar Mula Castellón

Administration and Management
Shock, Organ Dysfunction and Resuscitation
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.